Active Diabetes, Hormones & Metabolism Digestion, Kidneys & Other Organs

Carbohydrate sulfatases: A role in chronic bowel disease?

In plain English

AI plain-English summary

The mucus lining of the human colon is 80% sugar by weight, and bacteria living in the gut use specialised enzymes called carbohydrate sulfatases to chew through it. When those bacteria degrade too much of this protective mucus layer, the underlying gut tissue becomes inflamed, driving chronic bowel diseases like ulcerative colitis and raising the risk of colon cancer. Researchers now know which bacterial sulfatases are the key culprits, and that these enzymes sit on the bacterial cell surface or in the periplasm, making them accessible drug targets. This project will map the three-dimensional structures of these sulfatases to understand what determines which sugar they attack, identify which specific sulfatases actually cause disease in the gut, and then screen for small-molecule inhibitors that could block them. If successful, the work could lead to a new class of drugs that dial back bacterial mucus digestion in people with inflammatory bowel disease, preventing inflammation without wiping out the entire gut microbiome. This is fundamental molecular microbiology—there is no immediate clinical product—but similar structural work on bacterial enzymes has previously yielded antibiotics and antivirals.

View original technical description
The mucus lining of large colon forms a protective barrier between the bacterial community that inhabits the colon and the epithelial layer. Both experimental elimination, or excessive degradation of this mucus layer by colonic bacteria, leads to inflammation and thus chronic disease of the colon. Inflammation of the colon also increases the risk of colon cancer as well as being a precursor to it. Colonic mucin is a glycoprotein which is ~80 % carbohydrate by mass with these carbohydrates being heavily sulfated. The bacterial community in the distal colon are essential to human health, and metabolism of mucin, acts as a key nutrient and colonistaion factor but excessive degradation leads to disease. Carbohydrate sulfatases have been identified as key enzymes for bacteria to utilise colonic mucin. Furthermore, key sulfatases have been identified as exo acting and both cell surface exposed and periplasmic making them excellent drug targets to inhibit and thus, control mucin metabolism in individuals with inflammatory bowel disease. Here we propose an integrated molecule-to-function approach to: 1) Define structural features of bacterial carbohydrate sulfatases that determine substrate specificity 2) Identify which carbohydrate sulfatases elicit digestive tract disease 3) Identify small molecules that modulate sulfatase function.

View the original record at the funder ↗

Researchers

Alan Cartmell (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

What features of bacterial carbohydrate sulfatases can be exploited for human health?
The molecular basis of bacteria adhesion to gastrointestinal mucus
Uncovering the molecular strategies that allow human gut symbionts to degrade insoluble dietary and host glycans
Glycans as master triggers of health to intestinal inflammation transition
Mucin-derived sialic acid metabolism in gut bacteria

Original classification

Career Development Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.